<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

1 min read

On-Demand Webinar: Large-Scale LVV Production: Industry-Leading Process Development to High Quality GMP Vector

The on-demand webinar and Q&A “Large-Scale LVV Production: From Industry-Leading Process Development to High Quality GMP Vector,” with our own Giuliana Vallanti, Director of Development and Global R&D, Cell and Gene Therapy, and the panel of co-hosts is now available to watch for free.

About the Webinar

In recent years, Lentiviral vector (LVV) has become a vector of choice used in gene-modified cell therapy. A standard GMP 48L Cell Factory (CF)-based process is not enough to meet the manufacturing demand – especially for commercial applications. In response to this demand, AGC Biologics has developed a reproducible, high quality and quantity process for the industrial scale production of LVV. This platform consists of vector production in the iCELLis® Bioreactor, downstream purification and concentration by chromatography and TFF steps, and sterile filtration & filling.

Giuliana shared the latest data that demonstrates the key advantages of our proven approach to scale the LVV production process (48L CF) in a bioreactor (200L) without changing critical quality attributes (CQA).

Register to watch for free today.

This webinar was presented in partnership with InsightsBio.